LUCIANA NARDINELLI

(Fonte: Lattes)
Índice h a partir de 2011
5
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 10 de 17
  • conferenceObject
    Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country
    (2020) BRANDAO, Antonio Adolfo Guerra Soares; FATOBENE, Giancarlo; ABDO, Andre; LAGE, Luis Alberto De Padua Covas; BENDIT, Israel; NARDINELLI, Luciana; SIQUEIRA, Sheila Aparecida Coelho De; LEVY, Debora; PEREIRA, Juliana; REGO, Eduardo M.; ROCHA, Vanderson
  • conferenceObject
    PARACOCCIDIOIDOMYCOSIS AS A NEW (AND AWAITED) INFECTIOUS DISEASE IN GATA2 DEFICIENCY
    (2016) MORAES-VASCONCELOS, Dewton; MOREIRA, Nathalia; RUIZ, Antonio Lancha; NARDINELLI, Luciana; BARROS, Noac Chuffi; KHOURY, Zarifa; BENDIT, Israel
  • article 24 Citação(ões) na Scopus
    Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia
    (2012) NARDINELLI, Luciana; SANABANI, Sabri Saeed; DIDONE, Alline; FERREIRA, Patricia de Barros; SERPA, Mariana; NOVAES, Mafalda Megumi Yoshinaga; MARCHIANI, Mariana; RUIZ, Antonio Lancha; LIMA, Ismael Severino; CHAMONE, Dalton de Alencar Fischer; BENDIT, Israel
    In this retrospective study we evaluated the pretherapeutic mRNA expression of the hOCT1 (human organic cation transporter 1) gene in patients with chronic-phase (CP) chronic myeloid leukemia (CML) who varied in terms of their response to imatinib (IM). hOCT1 mRNA was quantified by real-time PCR. Patients were classified as expressing either high (n = 44) or low hOCT1 mRNA (n = 44). The complete cytogenetic response rates observed at 6, 12 and 18 months were 47.7, 84.1 and 91%, respectively, in patients with high hOCT1 mRNA and 47.5, 81.8 and 86.3%, respectively, in patients with low hOCT1 transcripts. The major molecular response rates were not significantly different between patients with high and low hOCT1 mRNA after 6 months of therapy (22.7 vs. 9.1%; p = 0.07), but they were significantly different after 12 months (54.5 vs. 31.8%; p = 0.026) and 18 months (77.2 vs. 56.8%; p = 0.034). Complete molecular responses were observed in 5 patients with low and 17 patients with high hOCT1 mRNA (p = 0.003). The 5-year event-free and overall survival analyses revealed no significant differences between the groups. These data imply that knowledge of the pretherapeutic level of hOCT1 could be a useful marker to predict IM therapy outcome in treatment-naive CP CML patients.
  • article 7 Citação(ões) na Scopus
    Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute
    (2012) BENDIT, Israel; SANABANI, Sabri Saeed; CONCHON, Monika; SERPA, Mariana; NOVAES, Mafalda Megumi Yoshinaga; NARDINELLI, Luciana; PEREIRA, Thales Dalessandro Meneguin; TUCUNDUVA, Luciana; FERREIRA, Patricia de Barros; DORLHIAC-LLACER, Pedro Enrique; CHAMONE, Dalton de Alencar Fischer
    Here we compare the management and survival outcomes of chronic myeloid leukemia (CML) patients who had early or late imatinib mesylate (IM) therapy. The cytogenetic and molecular responses of 189 CML patients were analyzed. Of this group, 121 patients were classified as the early chronic phase (ECP) group and started IM within 12 months of diagnosis. The other 68 patients were classified as the late chronic phase (LCP) group who had been treated with interferon (IFN)-alpha-2 and crossed over to IM more than 12 months after diagnosis. The overall rates of complete cytogenetic response (CCyR) and major molecular response (MMR) at last follow-up were 83.6 and 78.1% in the ECP and LCP groups, respectively. The CCyR rates were 89.3 (for ECP patients) versus 73.5% (for LCP patients; p < 0.0001). At last follow-up, 82.4% ECP and 64.2% LCP patients had achieved an MMR (p < 0.0001). No significant differences were noted between the two groups with regard to survival outcomes. Our experience reveals that IM is an effective rescue therapy in most CML LCP patients who are intolerant or in whom IFN-alpha therapy fails. Such therapeutic options should be considered in LCP patients, particularly in countries where IM may not be available.
  • article 1 Citação(ões) na Scopus
    Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia
    (2012) SERPA, Mariana; SANABANI, Sabri S.; DORLHIAC-LLACER, Pedro Enrique; NARDINELLI, Luciana; FERREIRA, Patricia de Barros; MARTINS, Thays Fernanda Borges; SEGURO, Fernanda; BENDIT, Israel
    Despite the beneficial effects of imatinib mesylate, some patients may either not respond or respond suboptimally. Here, we report two chronic myelogenous leukemia patients; one had a suboptimal response according to European LeukemiaNet criteria (a major molecular response was not achieved after 18 months of standard-dose imatinib therapy) and the other had failure with a standard dose of imatinib. At the time of the suboptimal response in patient 1 and the failure in patient 2, we were able to detect the F359I mutation in the BCR-ABL tyrosine kinase domain using DNA sequencing in both patients. Therefore, it was decided to change the therapeutic regimen to dasatinib at a dose of 100 mg once daily in both patients. This change resulted in the achievement of complete cytogenetic remission in patient 1 after 4 months and a major molecular response within 2 and 3 months in both patients. Detection of the F359I mutation in our two cases likely explains the suboptimal response to imatinib in case 1 and the failure in case 2. This implies that in such cases dasatinib should be considered to effectively suppress the mutated clones.
  • conferenceObject
    Treatment-Free Response in Chronic Myeloid Leukemia Using Brazilian Imatinib Copies As First Line - Results from Two Prospective Clinical Trials
    (2022) CENTRONE, Renato Torrescasana; SEGURO, Fernanda S.; BELLESSO, Marcelo; NARDINELLI, Luciana; BENDIT, Israel; ROCHA, Vanderson; ALVES, Adelson
  • article 22 Citação(ões) na Scopus
    Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance
    (2013) REZENDE, Vinícius Marcondes; RIVELLIS, Ariane Julio; GOMES, Melissa Medrano; DöRR, Felipe Augusto; NOVAES, Mafalda Megumi Yoshinaga; NARDINELLI, Luciana; COSTA, Ariel Lais de Lima; CHAMONE, Dalton de Alencar Fisher; BENDIT, Israel
    OBJECTIVE: The goal of this study was to monitor imatinib mesylate therapeutically in the Tumor Biology Laboratory, Department of Hematology and Hemotherapy, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP). A simple and sensitive method to quantify imatinib and its metabolite (CGP74588) in human serum was developed and fully validated in order to monitor treatment compliance. METHODS: The method used to quantify these compounds in serum included protein precipitation extraction followed by instrumental analysis using high performance liquid chromatography coupled with mass spectrometry. The method was validated for several parameters, including selectivity, precision, accuracy, recovery and linearity. RESULTS: The parameters evaluated during the validation stage exhibited satisfactory results based on the Food and Drug Administration and the Brazilian Health Surveillance Agency (ANVISA) guidelines for validating bioanalytical methods. These parameters also showed a linear correlation greater than 0.99 for the concentration range between 0.500 µg/mL and 10.0 µg/mL and a total analysis time of 13 minutes per sample. This study includes results (imatinib serum concentrations) for 308 samples from patients being treated with imatinib mesylate. CONCLUSION: The method developed in this study was successfully validated and is being efficiently used to measure imatinib concentrations in samples from chronic myeloid leukemia patients to check treatment compliance. The imatinib serum levels of patients achieving a major molecular response were significantly higher than those of patients who did not achieve this result. These results are thus consistent with published reports concerning other populations.
  • article 12 Citação(ões) na Scopus
    Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms
    (2020) SEGURO, Fernanda Salles; TEIXEIRA, Larissa Lane Cardoso; ROSA, Lidiane Ines da; SILVA, Wellington Fernandes da; NARDINELLI, Luciana; BENDIT, Israel; ROCHA, Vanderson
    Few data are available regarding epidemiology and outcomes of Philadelphia-negative chronic myeloproliferative neoplasms (MPN) in Latin America. Therefore, current models for MPN treatment are based in large cohorts of patients from Europe and North America. In this paper, we conducted a retrospective study to evaluate thrombotic and bleeding events in a cohort of patients with MPN from a reference center in Brazil. A total of 334 patients were included, being essential thrombocythemia the most common diagnosis. Here, we found that 41% of the MPN patients had a thrombotic event prior to the diagnosis. Thrombosis was more frequent in patients under 60 years-old. In a multivariable model, only JAK2 V617F mutation (OR 2.57 95% CI 1.58-4.18, p < 0.001) and presence of two cardiovascular risk factors (OR 1.90 95% CI 1.21-2.98, p < 0.005) were significant for thrombosis. The risk of thrombosis was similar among all subtypes of MPN. Cumulative incidence of thromboembolic event at 5 years from diagnosis was 5.8% (95% CI 3.5-8.9), which is similar to previous studies. The high incidence of thromboembolic events in younger patients suggests that socioeconomic disparities might have a role in the outcomes of MPN
  • conferenceObject
    Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults
    (2019) SILVA, Wellington F.; ROSA, Lidiane Ines Da; SEGURO, Fernanda S.; SILVEIRA, Douglas R. A.; NARDINELLI, Luciana; BUCCHERI, Valeria; VELLOSO, Elvira D. R. P.; ROCHA, Vanderson; REGO, Eduardo M.
  • conferenceObject
    Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials
    (2019) PAGNANO, Katia B.; SEGURO, Fernanda S.; MIRANDA, Eliana C.; LOPES, Ana Beatriz Pascoal; ABDO, Andre; DELAMAIN, Marcia Torresan; PEREIRA, Thales; DUARTE, Gislaine Borba; SANTOS, Fernanda Maria; VIANNA, Jessica C. N.; SILVA, Matheus Sebastian Da; NARDINELLI, Luciana; POVOA, Valquiria; PAVAN, Graziele; VERGILIO, Bruna R.; ROCHA, Vanderson; SOUZA, Carmino Antonio; PAULA, Erich V. De; BENDIT, Israel